ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event
November 12, 2021Merck announced the initiation of VICTOR (vericiguat in adults with Chronic heart failure and Reduced ejection fraction), a pivotal Phase 3 randomized, placebo-controlled cardiovascular clinical trial... -
Merck’s vericiguat meets primary endpoint in VICTORIA trial
April 01, 2020Merck said that its orally administered soluble guanylate cyclase (sGC) stimulator vericiguat met the primary efficacy endpoint in the phase 3 VICTORIA trial in heart failure patients.
Pharma Sources Insight January 2025
